

Washington University School of Medicine

Digital Commons@Becker

---

2020-Current year OA Pubs

Open Access Publications

---

6-27-2023

## Epigenome-wide association study identifies novel genes associated with ischemic stroke

Hao Peng

*Soochow University*

Helena Palma-Gudiel

*University of Florida*

Carolina Soriano-Tarraga

*Washington University School of Medicine in St. Louis*

Jordi Jimenez-Conde

*Universitat Pompeu Fabra*

Mingzhi Zhang

*Soochow University*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/oa\\_4](https://digitalcommons.wustl.edu/oa_4)



Part of the [Medicine and Health Sciences Commons](#)

## Please let us know how this document benefits you.

---

### Recommended Citation

Peng, Hao; Palma-Gudiel, Helena; Soriano-Tarraga, Carolina; Jimenez-Conde, Jordi; Zhang, Mingzhi; Zhang, Yonghong; and Zhao, Jinying, "Epigenome-wide association study identifies novel genes associated with ischemic stroke." *Clinical Epigenetics*. 15, 1. 106 (2023).

[https://digitalcommons.wustl.edu/oa\\_4/2857](https://digitalcommons.wustl.edu/oa_4/2857)

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact [vanam@wustl.edu](mailto:vanam@wustl.edu).

---

**Authors**

Hao Peng, Helena Palma-Gudiel, Carolina Soriano-Tarraga, Jordi Jimenez-Conde, Mingzhi Zhang, Yonghong Zhang, and Jinying Zhao

RESEARCH

Open Access



# Epigenome-wide association study identifies novel genes associated with ischemic stroke

Hao Peng<sup>1†</sup>, Helena Palma-Gudiel<sup>2†</sup>, Carolina Soriano-Tarraga<sup>3,4,5,6</sup>, Jordi Jimenez-Conde<sup>3</sup>, Mingzhi Zhang<sup>1</sup>, Yonghong Zhang<sup>1\*</sup> and Jinying Zhao<sup>2\*</sup>

## Abstract

**Background** DNA methylation has previously been associated with ischemic stroke, but the specific genes and their functional roles in ischemic stroke remain to be determined. Here we aimed to identify differentially methylated genes that play a functional role in ischemic stroke in a Chinese population.

**Results** Genome-wide DNA methylation assessed with the Illumina Methylation EPIC Array in a discovery sample including 80 Chinese adults (40 cases vs. 40 controls) found that patients with ischemic stroke were characterized by increased DNA methylation at six CpG loci (individually located at *TRIM6*, *FLRT2*, *SOX1*, *SOX17*, *AGBL4*, and *FAM84A*, respectively) and decreased DNA methylation at one additional locus (located at *TLN2*). Targeted bisulfite sequencing confirmed six of these differentially methylated probes in an independent Chinese population (853 cases vs. 918 controls), and one probe (located at *TRIM6*) was further verified in an external European cohort (207 cases vs. 83 controls). Experimental manipulation of DNA methylation in engineered human umbilical vein endothelial cells indicated that the identified differentially methylated probes located at *TRIM6*, *TLN2*, and *FLRT2* genes may play a role in endothelial cell adhesion and atherosclerosis.

**Conclusions** Altered DNA methylation of the *TRIM6*, *TLN2*, and *FLRT2* genes may play a functional role in ischemic stroke in Chinese populations.

**Keywords** DNA methylation, Ischemic stroke, EWAS, CRISPR/dCas9-Dnmt3a, Chinese population

<sup>†</sup>Hao Peng and Helena Palma-Gudiel should be noted as co-first authors.

\*Correspondence:

Yonghong Zhang

yhzhang@suda.edu.cn

Jinying Zhao

jzhao66@ufl.edu

<sup>1</sup> Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, 199 Renai Road, Suzhou 215123, China

<sup>2</sup> Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, 2004 Mowry Road, Gainesville, FL 32610, USA

<sup>3</sup> Neurovascular Research Group, Department of Neurology of Hospital del Mar-IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona/DCEXS, Universitat Pompeu Fabra, Barcelona, Spain

<sup>4</sup> Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA

<sup>5</sup> Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA

<sup>6</sup> NeuroGenomics and Informatics, Department of Psychiatry, Washington University in St. Louis, St. Louis, USA




### Background

Stroke is one of the leading causes of mortality and morbidity worldwide, second only to ischemic heart disease (IHD) [1]. In China, stroke mortality surpasses that of IHD, accounting for around one-third of all stroke cases worldwide [2]. Ischemic stroke (IS) constitutes more than 80% of all stroke cases [3]. The etiology of IS is multifactorial, involving both genetic and environmental factors [4, 5]. Despite the known contribution of genetic factors to the etiology of stroke, genetic variants identified so far explain less than 10% of the disease variability, suggesting that other factors may also play an important role in IS. Additionally, identified genetic risk variants for stroke confer race-specific effects [6], revealing the existence of underlying biological mechanisms that might explain the variability of stroke prevalence across different ancestries. The epigenome responds to a wide range of environmental stressors, providing a mechanism through which environmental factors affect the susceptibility to human complex diseases, including IS. Several epigenome-wide association studies (EWAS) have reported associations of altered DNA methylation with IS [7–12]. However, prior studies were mostly conducted in

European populations and results were largely inconsistent. Moreover, few studies have attempted to functionally validate the identified epigenetic markers in cellular models [13]. Here, we used a multi-stage design to identify DNA methylation alterations associated with IS in Chinese participants: (1) EWAS in a discovery Chinese cohort (discovery stage, n = 80); (2) confirmation and fine mapping of candidate regions by targeted methylation sequencing in an independent Chinese population (internal validation, n = 1,771); (3) replication in a European population (external replication, n = 390); and (4) functional validation of top hits in an endothelial cell model via the CRISPR/dCas9-Dnmt3a system.

### Results

The study design is illustrated in Fig. 1. Genome-wide DNA methylation was assessed with the Illumina Methylation EPIC Array in a discovery sample including 80 Chinese adults (40 cases vs. 40 controls). Differentially methylated probes (DMPs) identified were further confirmed by targeted bisulfite sequencing (TBS) in an independent sample (n = 1,771), followed by external replication in a European cohort (n = 390). The potential



**Fig. 1** A flowchart illustrating the study design and selection of participants. In the discovery stage, 40 CATIS IS cases and 40 PMMS controls were randomly selected to identify potential epigenetic markers of IS. From the remaining CATIS and PMMS participants, 1000 cases and 1000 age- and sex-matched controls were randomly selected as an internal replication sample to further confirm epigenetic markers of IS; after QC, 853 cases and 918 controls remained for downstream analysis. Additionally, an external cohort of 390 Spanish participants was used for further validation of the DMPs identified. To test the causal effect on gene expression of DNA methylation at loci identified in the aforementioned stages, human umbilical vein endothelial cell (HUVEC) models were epigenetically modified via CRISPR/dCas9-Dnmt3a. DMG, differentially methylated gene; DMP, differentially methylated probe; DMR, differentially methylated region; HUVEC, human umbilical vein endothelial cell; IS, ischemic stroke; TBS, targeted bisulfite sequencing

functional role of DMPs was verified in a CRISPR/dCas9-Dnmt3a model in human umbilical vein endothelial cells (HUVECs). Clinical characteristics of participants in each stage are shown in Table 1. Compared with healthy controls, IS cases had more risk factors such as hypertension, diabetes, and dyslipidemia in participants at all stages.

**DMPs identified in association with IS**

Of the 815,017 CpG sites tested, single-probe analysis identified 46 differentially methylated positions (DMPs) associated with IS at  $P < 1.0 \times 10^{-5}$  (Table 2), after adjusting for potential confounding factors in the discovery sample. Seven (out of 46) DMPs had  $q < 0.05$  (Fig. 2) after further correction for multiple testing via FDR. Of these 7 DMPs, 6 DMPs (cg15137954 in *TRIM6*, cg11199713 in *SOX1*, cg07913294 in *AGBL4*, cg16800165 in *FLRT2*, cg11533098 in *FAM84A*, and cg15949239 in *TLN2*) were successfully confirmed ( $q \leq 0.05$ ) by targeted bisulfite sequencing (TBS) in an independent Chinese population comprising 853 cases and 918 controls (Table 3). In addition, altered DNA methylation at neighboring CpGs showed significant associations with IS in the same directions (region-based  $P < 5 \times 10^{-7}$ ). Among these 6 DMPs validated in the Chinese cohorts, one probe (cg15137954) was also significantly associated with IS (same direction) in the European cohort (multiple testing adjusted  $P = 0.01$ ). Complete statistics for the external validation are included in Table 3.

**Functional validation in cellular models**

To test the potential impact of DNA methylation at the CpG sites identified in a relevant tissue for stroke pathogenesis, the CRISPR/dCas9-Dnmt3a system was used to experimentally induce increased DNA methylation levels in the gene regions of interest in human umbilical endothelial cells (HUVECs). After generating the epigenetically modified cells, pyrosequencing was used to check the validity of the model, i.e., to ascertain increased DNA methylation levels in the CRISPR-modified cells. Of the 7 DMPs identified in the discovery stage, DNA methylation levels of 3 CpG sites (cg15137954, cg16800165, and cg15949239) in the engineered HUVECs were two times higher when compared to the negative control cells, denoting successful construction of the cellular models by the CRISPR/dCas9-Dnmt3a system (Fig. 3). The other 4 CpG sites (cg24891539, cg11199713, cg07913294, and cg11533098) exhibited similar methylation levels when comparing the two groups (Fig. 3). Gene expression analysis by qRT-PCR revealed that, compared to the negative control cells, the dCas9-Dnmt3a engineered HUVECs with an increased methylation level at cg15137954 (located in the *TRIM6* gene) resulted in decreased expression of the *TRIM6*, *VCAM1*, and *SELE* genes (Fig. 4a). In contrast, enhanced methylation at cg16800165 (located in *FLRT2*) led to reduced expression of the *FLRT2* gene and increased expression of the endothelial cell adhesion marker genes *ICAM1*, *VCAM1*, and *SELE* (Fig. 4b). In addition, increased DNA

**Table 1** Clinical characteristics of study participants in the discovery and replication samples at enrollment

	Discovery cohort (n = 80)			Internal validation (n = 1,771)			External replication (n = 390)		
	Controls N = 40	Cases N = 40	P-value	Controls N = 918	Cases N = 853	P-value	Controls N = 183	Cases N = 207	P-values
Age, years	65.6 ± 6.2	65.6 ± 6.2	0.986	61.2 ± 12.2	62.5 ± 12.1	0.026	64	71	< 0.001
Sex, men (%)	30 (75)	30 (75)	1.000	503 (55)	453 (53)	0.507	(48)	(64)	< 0.001
Current smoking, n (%)	16 (40)	14 (35)	0.817	348 (38)	294 (34)	0.118	2 (1)	49 (22)	< 0.001
Current drinking, n (%)	24 (60)	15 (37.5)	0.074	253 (28)	222 (26)	0.500	NA	NA	NA
Hypertension	5 (12.5)	27 (67.5)	< 0.001	325 (35)	670 (79)	< 0.001	107 (59)	74 (34)	< 0.001
BMI, kg/m <sup>2</sup>	24.7 ± 3.1	24.8 ± 3.0	0.825	22.4 ± 3.4	25.1 ± 3.4	< 0.001	28.1	26.6	< 0.001
SBP, mmHg	129.6 ± 9.1	165.7 ± 18.1	< 0.001	134.6 ± 20.7	168.1 ± 16.8	< 0.001	NA	NA	NA
DBP, mmHg	77.9 ± 6.8	94.7 ± 10.9	< 0.001	80.0 ± 10.8	97.0 ± 10.7	< 0.001	NA	NA	NA
Fasting glucose, mmol/L, diabetes mellitus*, n (%)	5.5 ± 1.1	7.2 ± 3.0	0.001	5.0 ± 1.2	6.8 ± 2.8	< 0.001	30 (16)	81 (37)	< 0.001
Triglycerides, mmol/L Hyperlipidemia†, n (%)	1.3 ± 0.7	1.6 ± 1.1	0.244	1.6 ± 1.2	1.9 ± 5.0	0.054	124 (68)	123 (56)	< 0.001
Total cholesterol, mmol/L	5.3 ± 0.9	5.0 ± 1.3	0.402	4.7 ± 1.0	5.1 ± 1.2	< 0.001	NA	NA	NA
LDL cholesterol, mmol/L	3.1 ± 0.8	2.8 ± 1.2	0.216	3.2 ± 1.0	2.9 ± 1.0	< 0.001	NA	NA	NA
HDL cholesterol, mmol/L	1.5 ± 0.4	1.4 ± 0.4	0.168	1.3 ± 0.3	1.3 ± 0.4	0.032	NA	NA	NA


All results are expressed as mean ± SD, unless otherwise noted. \*Fasting glucose was not available in the external replication cohort, and thus presence/absence of diabetes mellitus was used for comparison. †Total triglycerides and cholesterol were not available in the external replication cohort; thus, presence/absence of hyperlipidemia was used for comparison. BMI, body mass index; DBP, diastolic blood pressure; IS, ischemic stroke; SBP, systolic blood pressure

**Table 2** Significant DMPs associated with ischemic stroke in the discovery sample ( $P < 1 \times 10^{-5}$ )

CpG	Genomic coordinates	Nearest gene	Gene location	Effect size*	P-value	q-value†
cg15137954	Chr11:5618023	<i>TRIM6</i>	TSS200	-0.04	$4.76 \times 10^{-9}$	0.004
cg24891539	Chr8:55370407	<i>SOX17</i>	TSS200	-0.09	$6.28 \times 10^{-8}$	0.025
cg15949239	Chr15:62988566	<i>TLN2</i>	Body	0.04	$1.93 \times 10^{-7}$	0.039
cg11199713	Chr13:112721773	<i>SOX1</i>	TSS200	-0.05	$1.94 \times 10^{-7}$	0.039
cg07913294	Chr1:50489574	<i>AGBL4</i>	5'UTR	-0.04	$2.98 \times 10^{-7}$	0.044
cg16800165	Chr14:85996364	<i>FLRT2</i>	TSS200	-0.04	$3.24 \times 10^{-7}$	0.044
cg11533098	Chr2:14775132	<i>FAM84A</i>	3'UTR	-0.04	$4.09 \times 10^{-7}$	0.048
cg12076203	chr2:27145848	<i>DPYSL5</i>	Body	0.05	$6.00 \times 10^{-7}$	0.061
cg20931033	chr1:50489577	<i>AGBL4</i>	1stExon	-0.05	$8.60 \times 10^{-7}$	0.070
cg17814180	chr7:86274020	<i>GRM3</i>	1stExon	-0.03	$9.49 \times 10^{-7}$	0.070
cg16586689	chr18:46082474	<i>CTIF</i>	5'UTR	0.04	$1.02 \times 10^{-6}$	0.070
cg27646412	chr10:77501817	<i>C10orf11</i>	TSS1500	0.06	$1.31 \times 10^{-6}$	0.070
cg15852516	chr8:17270812	<i>MTMR7</i>	1stExon	-0.04	$1.31 \times 10^{-6}$	0.070
cg21426003	chr2:237076811	<i>GBX2</i>	TSS200	-0.16	$1.38 \times 10^{-6}$	0.070
cg08582701	chr16:6070005	<i>A2BP1</i>	5'UTR	-0.05	$1.40 \times 10^{-6}$	0.070
cg14615336	chr1:50489567	<i>AGBL4</i>	1stExon	-0.03	$1.43 \times 10^{-6}$	0.070
cg13929328	chr10:129535898	<i>FOXL2</i>	1stExon	-0.04	$1.50 \times 10^{-6}$	0.070
cg03135713	chr13:46961897	<i>C13orf18</i>	TSS1500	0.06	$1.54 \times 10^{-6}$	0.070
cg23093589	chr7:20824932	<i>SP8</i>	Body	-0.06	$2.07 \times 10^{-6}$	0.085
cg12789173	chr11:118084192	<i>AMICA1</i>	TSS200	-0.09	$2.08 \times 10^{-6}$	0.085
cg06950070	chr19:6502301	<i>TUBB4</i>	1stExon	0.05	$2.33 \times 10^{-6}$	0.091
cg05387519	chr1:50489730	<i>AGBL4</i>	TSS200	-0.09	$2.51 \times 10^{-6}$	0.093
cg16532100	chr5:171611704	<i>STK10</i>	Body	-0.03	$2.83 \times 10^{-6}$	0.095
cg01756381	chr4:11430693	<i>HS3ST1</i>	TSS200	-0.09	$2.89 \times 10^{-6}$	0.095
cg05362127	chr3:55515543	<i>WNT5A</i>	TSS200	-0.04	$2.92 \times 10^{-6}$	0.095
cg02294868	chr8:79579003	<i>ZC2HC1A</i>	5'UTR	-0.02	$3.29 \times 10^{-6}$	0.100
cg18517195	chr15:71184476	<i>LRRC49;THAP10</i>	TSS1500;1stExon	-0.04	$3.32 \times 10^{-6}$	0.100
cg26026615	chr12:115130855			-0.06	$3.67 \times 10^{-6}$	0.107
cg00787188	chr2:213403315	<i>ERBB4</i>	1stExon	-0.05	$4.93 \times 10^{-6}$	0.134
cg13424673	chr1:50489744	<i>AGBL4</i>	TSS200	-0.03	$4.93 \times 10^{-6}$	0.134
cg00903099	chr7:154862441	<i>HTR5A</i>	TSS200	-0.08	$5.29 \times 10^{-6}$	0.139
cg24637364	chr1:66259084	<i>PDE4B</i>	5'UTR	-0.12	$5.74 \times 10^{-6}$	0.146
cg10862431	chr12:63544783	<i>AVPR1A</i>	TSS200	-0.04	$6.24 \times 10^{-6}$	0.154
cg00107187	chr14:105070998	<i>TMEM179</i>	1stExon	-0.05	$6.90 \times 10^{-6}$	0.164
cg21590264	chr5:37834850	<i>GDNF</i>	1stExon	-0.04	$7.39 \times 10^{-6}$	0.164
cg21180443	chr11:66984956	<i>KDM2A</i>	TSS200	-0.02	$7.51 \times 10^{-6}$	0.164
cg03609960	chr12:99288805	<i>ANKS1B</i>	TSS200	-0.04	$7.61 \times 10^{-6}$	0.164
cg01546873	chr5:122523277	<i>PRDM6</i>	3'UTR	0.05	$7.78 \times 10^{-6}$	0.164
cg08146323	chr19:57183118	<i>ZNF835</i>	1stExon	-0.07	$7.88 \times 10^{-6}$	0.164
cg07664198	chr7:136553882	<i>CHRM2</i>	1stExon	-0.04	$8.07 \times 10^{-6}$	0.164
cg12842973	chr20:56650428			-0.06	$8.54 \times 10^{-6}$	0.166
cg00455526	chr7:28996196	<i>TRIL</i>	1stExon	-0.10	$8.67 \times 10^{-6}$	0.166
cg19524676	chr5:17218547	<i>BASP1</i> ; <i>LOC285696</i>	5'UTR; TSS1500	-0.04	$8.74 \times 10^{-6}$	0.166
cg15439862	chr18:28622593	<i>DSC3</i>	1stExon	-0.04	$9.05 \times 10^{-6}$	0.168
cg05824976	chr2:203737195	<i>ICA1L</i>	TSS1500	0.07	$9.60 \times 10^{-6}$	0.172
cg07514158	chr16:24267526	<i>CACNG3</i>	1stExon	-0.03	$9.68 \times 10^{-6}$	0.172

\* Difference in mean DNA methylation level between cases and controls (i.e., negative values indicate stroke cases were hypomethylated; positive values indicate stroke cases were hypermethylated at the specific CpG site)

† Adjusting for a total of 815,017 CpG sites using the false discovery rate (FDR) method



**Fig. 2** EWAS in the discovery stage. Manhattan (a) and volcano (b) plots displaying the associations of DNA methylation at 815,017 CpGs with IS in a Chinese sample (40 cases and 40 matched controls). In the Manhattan plot, X-axis indicates the chromosome position; Y-axis indicates the  $-\log_{10} P$ -values. The red line denotes the significance threshold at  $q$ -value  $< 0.05$ . In the volcano plot, blue and red dots highlight significantly hypomethylated and hypermethylated CpG sites, respectively, in cases with respect to controls. c Box plots showing the differences in mean DNA methylation level between cases and controls at the 7 CpG sites significantly associated with IS in the discovery stage

methylation at cg15949239 (located at *TLN2*) was associated with a heightened expression of the *TLN2* gene together with decreased expression of the cell adhesion marker genes *ICAM1*, *VCAM1*, and *SELE* (Fig. 4c). Together, these findings suggest that DNA methylation levels at the identified CpG sites regulate gene expression of their corresponding genes; additionally, it points to a functional role of the identified DMPs in endothelial cell activation and vascular inflammation.

**DMRs identified in association with IS in the discovery sample**

Region-based analysis identified 149 DMRs (annotated to 168 unique genes) significantly associated with IS at  $q < 0.05$  (Fig. 5a, Additional file 1: Table S1). Of these, 129 DMRs were hypomethylated and 20 DMRs were hypermethylated in relation to IS (Fig. 5b). The identified

DMRs are mainly located in the first exon and promoter regions. With respect to CpG context, the identified DMRs are largely located within CpG Islands (Fig. 5c).

**Functional annotation of the differentially methylated genes associated with IS**

The 7 DMPs and 149 DMRs identified in the discovery sample were annotated to 170 unique genes. These genes were significantly enriched in 351 GO biological processes including neuron differentiation, neurogenesis, and cell–cell signaling (Additional file 1: Table S2), 37 GO cellular components including neuron and cell junction (Additional file 1: Table S3), and 12 GO molecular functions including DNA binding transcription factor activity (Additional file 1: Table S4). The same gene set was also enriched in several GTEx tissues, including brain, thyroid, nerves, and blood vessels

**Table 3** DMPs significantly associated with ischemic stroke in the discovery ( $q < 0.05$ ) and replication samples

CpG	Genomic coordinates	Nearest gene	Gene location	Discovery sample (n = 80)		Internal replication (n = 1,771)		External replication (n = 390)				
				Δ methylation*	P-value	q-value†	Δ methylation*	P-value	q-value‡	Δ methylation*	P-value	q-value‡
cg15137954	Chr11:5618023	TRIM6	TSS200	-4.4%	$4.76 \times 10^{-09}$	0.004	-2.1%	$1.28 \times 10^{-41}$	$7.65 \times 10^{-41}$	-4.9%	0.01	0.05
cg24891539	Chr8:55370407	SOX17	TSS200	-6.5%	$6.28 \times 10^{-08}$	0.025	NA	NA	NA	0.5%	0.04	0.08
cg15949239	Chr15:62988566	TLN2	Gene body	8.5%	$1.93 \times 10^{-07}$	0.039	1.9%	0.053	0.053	0.2%	0.62	0.62
cg11199713	Chr13:112721773	SOX1	TSS200	-3.4%	$1.94 \times 10^{-07}$	0.039	-1.2%	$2.27 \times 10^{-08}$	$2.73 \times 10^{-08}$	0.4%	0.31	0.44
cg07913294	Chr1:50489574	AGBL4	5'UTR	-2.9%	$2.98 \times 10^{-07}$	0.044	-1.1%	$1.34 \times 10^{-09}$	$2.01 \times 10^{-09}$	0.6%	0.09	0.15
cg16800165	Chr14:85996364	FLRT2	TSS200	-4.5%	$3.24 \times 10^{-07}$	0.044	-4.4%	$1.25 \times 10^{-09}$	$2.01 \times 10^{-09}$	0.2%	0.50	0.59
cg11533098	Chr2:14775132	FAM84A	3'UTR	-2.6%	$4.09 \times 10^{-07}$	0.048	-0.6%	$1.33 \times 10^{-13}$	$4.00 \times 10^{-13}$	0.7%	0.01	0.05

\* Difference in mean DNA methylation level between cases and controls. † Adjusting for a total of 815,017 CpG sites using the false discovery rate (FDR) method. ‡ Multiple testing was corrected by FDR. One probe (cg24891539) failed to be confirmed by targeted bisulfite sequencing in the internal validation cohort





**Fig. 3** Validation of the CRISPR/dCas9-Dnmt3a model construction in human umbilical vein endothelial cells (HUVEC). Pyrosequencing was used to measure DNA methylation levels in the engineered and control cells. Successful model construction was considered when DNA methylation level of the engineered cells was higher than that of the negative control (i.e., *TRIM6*, *FLRT2*, and *TLN2* genes). No significant differences in DNA methylation levels were observed for *SOX1*, *FAM84A*, *SOX17*, and *AGBL4* genes


(Additional file 1: Table S5). Finally, the identified differentially methylated genes were significantly enriched in GWAS risk genes associated with stroke-related phenotypes such as chronotype, obesity-related traits, coronary artery calcification, and blood pressure (Additional file 1: Table S6). These findings provide further support for the potential functional role of the identified genes in IS.

### Discussion


In this large-scale EWAS, we employed a multi-stage approach to identify peripheral blood DNA methylation patterns associated with IS in Chinese population. Specifically, we identified DNA methylation at 7 CpGs (annotated to 7 unique genes) significantly associated with IS. Of these, 6 CpGs (cg15137954 in *TRIM6*, cg07913294 in *AGBL4*, cg11533098 in *FAM84A*, cg24891539 in *SOX17*,

(See figure on next page.)

**Fig. 4** The expression of differentially methylated genes and genes encoding endothelial cell adhesion markers (i.e., *ICAM1*, *VCAM1*, and *SELE*) in site-specific methylation model HUVECs (dCase9-Dnmt3a) and negative control HUVECs. **(a)** *TRIM6* model: (left) methylation level at cg15137954 is higher in dCas9-Dnmt3a engineered cells than in negative control cells; (center) higher methylation is associated with decreased *TRIM6* expression; (right) decreased expression of *VCAM1* and *SELE* can be observed in dCas9-Dnmt3a engineered cells. **(b)** *FLRT2* model: (left) methylation level at cg16800165 is higher in dCas9-Dnmt3a engineered cells than in negative control cells; (center) *FLRT2* expression is significantly decreased in dCas9-Dnmt3a engineered cells; (right) expression of genes encoding endothelial cell adhesion markers is significantly increased in dCas9-Dnmt3a cells. **(c)** *TLN2* model: (left) methylation at cg15949239 is higher in dCas9-Dnmt3a cells than in the negative control cells; (center) *TLN2* expression is significantly increased in dCas9-Dnmt3a cells; (right) expression of genes encoding endothelial cell adhesion markers is significantly decreased in dCas9-Dnmt3a engineered cells when compared to negative control cells. Relative mRNA expression of dCase9-Dnmt3a to negative control was calculated using the  $2^{-(\Delta\Delta C(T))}$  method and normalized with the reference gene *Actin* (3 repeated measurements per group). Data are mean  $\pm$  SEM (standard error of mean). A Student t test was used to compare the group difference in gene expression levels. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001



**Fig. 4** (See legend on previous page.)



**Fig. 5** Manhattan (a) and volcano (b) plots displaying the differentially methylated regions (DMRs) associated with ischemic stroke in the discovery sample of 80 Chinese adults (40 cases vs. 40 matched controls). In the Manhattan plot, X-axis indicates the chromosome position; Y-axis indicates the  $-\log_{10} P$ -values. The red line denotes the significance threshold at  $q$ -value  $< 0.05$ . In the volcano plot, blue and red dots highlight significantly hypomethylated and hypermethylated DMRs, respectively, in cases with respect to controls. Genomic distribution and CpG context (c) of the identified DMRs indicated that these DMRs are mainly located in the first exon, promoter, and CpG Islands

cg16800165 in *FLRT2*, and cg15949239 in *TLN2*) were confirmed in an independent Chinese population, and one CpG (cg15137954, located in the *TRIM6* gene) was further verified in an independent cohort of European ancestry. Functional analysis in cellular models via the CRISPR/dCas9-Dnmt3a system revealed that DNA methylation at three genes (*TRIM6*, *FLRT2*, and *TLN2*) harboring the aberrantly methylated probes could regulate the expression of three endothelial cell adhesion markers (i.e., *ICAM1*, *VCAM1*, and *SELE*) and thus be functionally implicated in endothelial cell activation and leukocyte transendothelial migration [28], one of the mechanisms underlying atherosclerosis [29, 30] and stroke [31].

Of the differentially methylated genes identified, the observed association of DNA hypomethylation of the tripartite motif containing 6 (*TRIM6*) gene with IS is especially interesting. This gene belongs to the *TRIM* gene family, which has been associated with innate immunity, a mechanism known to be implicated in IS and atherosclerosis [32]. In this study, we found that experimentally

induced increased DNA methylation at the *TRIM6* locus resulted in decreased expression of the *TRIM6* gene as well as reduced expression of genes encoding two endothelial cell adhesion markers (*VCAM1* and *SELE*). These results point to an increased expression of *TRIM6*, *VCAM1*, and *SELE* in IS cases. The *TRIM6* gene was confirmed in both internal and external replications and further verified in the cellular models. Previous research in human cells has shown that several TRIM family genes (e.g., *TRIM5*, *TRIM34*) were upregulated in response to interferon gamma (IFN- $\gamma$ ) and lipopolysaccharide (LPS), while *TRIM5* protein was involved in the containment of viral spread in rhesus monkeys [33, 34]. Of note, acute viral infections have been suggested as potential triggers for IS due to destabilization and rupture of atherosclerotic plaques in humans [35, 36]. In addition, genetic polymorphisms in the *TRIM5/TRIM6* locus have previously been associated with coronary artery disease [37]. Moreover, *TRIM6* has been reported to aggravate myocardial ischemia/reperfusion injury in mice [38]. A genetic polymorphism at another TRIM family member (*TRIM36*)

has recently been associated with cardioembolic stroke, a subtype of ischemic stroke, in a genome-wide association analysis [39]. Together, these findings support a causal role of altered *TRIM6* gene methylation in the pathogenesis of IS.

The Talin 2 (*TLN2*) gene encodes a protein related to talin 1, a cytoskeletal protein that is involved in the assembly of actin filaments and the spreading and migration of various cell types, and may play an important role in cell adhesion [40]. Differential expression of the *TLN2* gene was previously reported to modulate carotid intima media thickness in European individuals [41]. Moreover, downregulation of the *TLN2* gene has been associated with atherosclerosis in human arterial plaque tissue samples [42]. In the present study, we found that stroke patients were characterized by *TLN2* hypermethylation, while in vitro modulation of DNA methylation at the *TLN2* locus via CRISPR/dCas9-Dnmt3a system revealed a positive association between *TLN2* methylation and *TLN2* expression. Moreover, *TLN2* methylation was negatively correlated with the expression of genes encoding endothelial cell adhesion markers. The *FLRT2* (fibronectin leucine-rich transmembrane protein 2) gene is expressed in pancreas, skeletal muscle, brain, and heart [43]. This gene was previously found to be involved in the regulation of early embryonic vascular and neural development [43], and a genetic polymorphism of the *FLRT2* gene has been associated with IS in African-Americans [44]. In this study, we found that stroke patients exhibited lower methylation level of the *FLRT2* gene compared to controls. Additionally, increased *FLRT2* methylation was associated with decreased *FLRT2* expression and increased expression of genes encoding endothelial cell adhesion markers. Together, these findings suggest that the observed changes in DNA methylation in *TLN2* and *FLRT2* genes in IS patients are associated with decreased gene expression levels of cell adhesion markers. These observations support the role of DNA methylation in responding to ischemic injury and highlight its potential role in stroke prognosis rather than its pathogenesis.

With regard to DMR findings, out of 149 DMRs identified, 2 DMRs were located in genes previously associated with stroke in a multi-ancestry GWAS: *FBN2* and *PDE3A* genes [39]. Interestingly, the SNP rs55670004 previously associated with IS has been identified as a methylation quantitative trait loci (mQTL) for CpG sites cg02271895 and cg17564775, both of which are included in the *FBN2* DMR (chr5:127,872,329–127,875,163) associated with IS in the current study. No mQTLs were found for *PDE3A* gene. These results highlight that at least some of the identified DMRs are driven by the underlying genetic background of assessed participants suggesting that DNA methylation at these regions might play a causal

role in stroke etiology. Additionally, 17 out of 168 unique genes located in close proximity to identified DMRs were already reported by a previous EWAS of IS in a Chinese population [11]. Of note, one of these 17 overlapping genes was *FBN2*, further highlighting its role in IS etiology.

In line with previous research [12], we found that the majority of the genes identified in our study, both in the DMP and DMR approaches, are hypomethylated with respect to stroke status (i.e., DNA methylation was lower in cases than in controls). The identified genes are significantly enriched in biological pathways involved in neurogenesis, neuron differentiation, and neuronal development, as well as nervous cellular components, such as neurons and synapses. These findings suggest that peripheral blood DNA methylation may serve as a proxy for DNA methylation in the brain, the target organ of stroke. Further studies in postmortem brain tissue will reveal whether the observed DNA methylation changes in blood of IS survivors are also present in brain tissue of deceased participants that underwent IS. Other pathways highlighted included cell adhesions, cell junctions, and extracellular matrix, all of which are known to be involved in leukocyte transendothelial migration and atherogenesis, a major contributor to IS [45]. Several pathways identified in the present study were also reported in a previous EWAS of IS in a Chinese population, including synapse assembly, synapse organization, and homophilic cell adhesion [11]. GWAS trait enrichment further revealed that genes associated with chronotype and sleep disturbances might be differentially methylated in IS participants. Chronotype, also known as diurnal preference, refers to activity-rest preference in a given 24-h period [46]. Of note, several sleep disturbances have previously been identified as a risk factor for stroke onset [47], while sleep duration has been linked with subclinical atherosclerosis [48]. Disruption of circadian rhythms in shift workers and in experimental models in mice and sheep increased reperfusion injury after myocardial infarction providing experimental evidence of the causal link between poor sleep patterns and worse prognosis after ischemic events [49]. Finally, the observation that several risk factors for stroke (i.e., obesity, body mass index, blood pressure, and smoking status, as summarized in Additional file 1: Table S6) were enriched in gene pathway analysis suggests that DNA methylation might mediate the deleterious effects of such risk factors, thus increasing IS risk.

Several limitations of our study merit discussion. First, DNA methylation was measured after the onset of stroke. Due to the dynamic nature of epigenetic mechanisms, identified differentially methylated genes could be involved in either stroke pathogenesis, ischemic injury,

or neuroprotection following IS. Further prospective longitudinal studies are warranted to test causality of observed DNA methylation changes. However, findings from our CRISPR/dCas9-Dnmt3a cell model suggest that the observed DNA methylation changes have antagonistic effects suggesting that we identified a mixture of stroke inducing (e.g., *TRIM6* gene) as well as neuroprotective (e.g., *TLN2* and *FLRT2* genes) epigenetic biomarkers. Second, given the tissue and cell type specificity of DNA methylation, blood DNA methylation may not reflect the changes in human brain. Nonetheless, previous research has shown that blood DNA methylation may partially reflect changes in the targeted tissue and thus can serve as proxy non-invasive markers [50]. Third, participants were not stratified by stroke etiology (i.e., large artery, small vessel, cardioembolic strokes). Fourth, it is well established that nutrition could not only affect DNA methylation but also contribute to the risk of stroke. Unfortunately, data on diet were not available in the cohorts involved in our study. We cannot prevent the confounding effects caused by nutrition, as well as other unmeasured confounding, on the association between DNA methylation and stroke in an observational study. Fifth, the sample size of the discovery cohort is relatively smaller than prior EWAS studies. However, we conducted an independent replication study with a larger sample size to exclude the probable false-positive results. All DMPs identified in the discovery cohort were successfully replicated, indicating that the small sample size of the discovery cohort may not affect our findings a lot. Finally, although we included an external validation, only one DMP was nominally associated with IS (same direction) in the European population. The lack of replication could be attributed to differences in genetic makeup, clinical diagnosis, environmental exposures, and recruitment procedures between the study populations. For example, blood collection following stroke was performed within 12 h in the European cohort and within 48 h in the Chinese cohort. Given the known epidemiological differences in stroke incidence among different countries, with stroke being the leading cause of mortality in China, it is possible that some of the reported genes herein are specific to the Chinese population. The robustness of our multi-stage study design, including initial discovery, technical verification by TBS, internal and external validation in human populations, as well as functional validation in vascular endothelial cell models supports the strength of the reported findings.

In summary, we identified novel genes associated with IS in Chinese population. These findings enhance the understanding of DNA methylation involvement in both stroke pathogenesis and response to ischemic injury and highlight the importance of functional validation in epigenome-wide association studies in future research.

## Methods

### Participants

The study design and selection of participants are illustrated in Fig. 1. In the discovery stage, 40 IS cases and 40 controls were randomly selected from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS, 2009–2016) and the Prevention of Metabolic syndrome and Multi-metabolic disorders Study (PMMS, 2000–2004), to identify potential epigenetic markers of IS. From the remaining CATIS and PMMS participants, 1000 cases and 1000 age- and sex-matched controls were randomly selected as an internal replication sample to further confirm epigenetic markers of IS; after QC, 853 cases and 918 controls remained for downstream analysis. Additionally, an external cohort of 390 Spanish participants was used for further validation of the DMPs identified. To test the causal effect on gene expression of DNA methylation at loci identified in the aforementioned stages, human umbilical vein endothelial cell (HUVEC) models were epigenetically modified via CRISPR/dCas9-Dnmt3a.

*Chinese cohorts* (discovery and internal validation) included adults from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS, 2009–2016) and the Prevention of Metabolic syndrome and Multi-metabolic disorders Study (PMMS, 2000–2004). Detailed study design and methods for both cohorts have been described elsewhere [14, 15]. Briefly, CATIS is a multicenter randomized clinical trial (NCT01840072) designed to test whether moderate lowering of blood pressure in the acute phase after the onset of IS can reduce mortality and major disability at 14 days or hospital discharge. A total of 4,071 patients who had first-ever IS within 48 h of symptom onset and had an elevated systolic blood pressure between 140 mmHg and less than 220 mmHg were recruited to the CATIS. PMMS is a community-based cohort study including 5,888 Chinese adults free of overt cardiovascular disease (CVD) at the time of enrollment. All participants in the CATIS and PMMS reside in the Changshu city, Jiangsu Province, China.

The *European cohort* (external replication) included Spanish individuals of European ancestry from the BasicMar Register and the Girona Heart Registry study (REGICOR). Detailed information for these cohorts has been described elsewhere [16, 17]. Briefly, BasicMar is a hospital-based registry of stroke patients admitted to the Hospital del Mar in Barcelona, Spain [16]. REGICOR is a population-based registry recruiting participants residing in Girona, Spain [17]. REGICOR participants with no previous history of IS and no previous history of acute myocardial infarction were included as controls in the current analysis.

### Study approval

The study protocols of CATIS were approved by the Institutional Review Boards at Soochow University in China and Tulane University in the USA. The study protocols of PMMS were approved by the Soochow University Ethics Committee. Written informed consent was obtained from all study participants. The study protocols of BasicMar and REGICOR were approved by the ethics committees of all participating hospitals, and all participants provided written informed consent to participate.

### Clinical data and blood sample collection

For participants in the Chinese cohorts, demographic and lifestyle information and disease history were collected using standard questionnaires, as previously described [18]. For CATIS participants, blood samples were collected within 48 h of stroke onset and then stored at  $-80^{\circ}\text{C}$  for biochemical and DNA methylation analysis. Fasting plasma glucose and blood lipids including total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured by standard laboratory methods [19]. IS was ascertained by computed tomography (CT) or magnetic resonance imaging (MRI) of the brain.

For participants in the BasicMar and REGICOR cohorts, information for disease history including vascular risk factors was obtained from personal interviews to the patients, relatives, or caregivers, or abstracted from medical records. IS diagnosis was confirmed by CT or MRI. Blood samples were collected at hospital arrival, in the acute phase of the stroke (within 12 h of symptoms onset).

### Epigenome-wide association study and confirmation by targeted bisulfite sequencing

#### Discovery stage

Forty cases and 40 age- and sex-matched controls were randomly selected from the CATIS and PMMS, respectively, for epigenome-wide association analysis. Briefly, genomic DNA was extracted from whole peripheral blood using the EZgene™ Blood DNA Kit (Biomega, Inc.), followed by bisulfite treatment using the EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA). DNA methylation was quantified by the Infinium HumanMethylationEPIC BeadChip array (Illumina, Inc., San Diego, CA). Raw DNA methylation data were processed using the R Bioconductor package “minfi” (v1.30.0) [20]. After quality control and exclusion of probes on the sex chromosomes, a total of 815,017 probes were used in the downstream analysis. Blood cell proportions (CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, natural killer cells, B cells, monocytes, and granulocytes) were estimated using the Houseman's estimation method [21].

### Fine mapping and internal replication

In an independent sample comprising 1000 cases from the CATIS and 1000 age- and sex-matched controls from the PMMS, targeted bisulfite sequencing (TBS) [22] was performed to confirm and discover more differentially methylated probes (DMPs) associated with IS. Briefly, primers were designed to detect the maximum number of additional CpG loci in the vicinity of identified DMPs. TBS target gene sequences and primers can be found in Additional file 1: Table S7. Genomic DNA was bisulfite-treated using the EZ DNA Methylation-Gold Kit (Zymo Research, Inc., CA, USA) according to the manufacturer's protocol. Samples were then amplified, barcoded, and sequenced by Illumina HiSeq 2000 (Illumina, Inc., CA, USA) using the paired-end sequencing protocol according to manufacturer's guidelines. Methylation level at each CpG locus was calculated as the percentage of the methylated alleles over the sum of methylated and unmethylated alleles. For quality control, the samples with bisulfite conversion rate < 98% and the cytosine sites with average coverage less than 20× were filtered out. After quality control, 853 cases and 918 controls remained for downstream analysis; all CpG sites passed quality control. Demographic and clinical characteristics of included (n = 1771) vs. excluded participants (n = 229) can be found in Additional file 1: Table S8.

### External replication

DNA methylation in the BasicMar and REGICOR was assessed by Infinium MethylationEPIC Beadchip arrays (Illumina Netherlands, Eindhoven, Netherlands), as previously reported [9]. A total of 390 individuals, including 207 cases from BasicMar and 183 controls from REGICOR, were included in the external replication analysis.

### Functional validation of DMPs in cellular models

To examine the potential functional role of the identified CpGs in vascular endothelial cell activation and inflammation, we employed the CRISPR/dCas9-Dnmt3a system to develop site-specific methylation models in a culture of human umbilical vein endothelial cells (HUVEC).

### Construction of CRISPR/dCas9-Dnmt3a plasmids

The dCas9-5xGCN4 fusion protein expression vector (ZP509, pEFS-dCas9-5xGCN4-T2A-EGFP) was generated by fusing cDNA encoding the catalytically inactive nuclease codon-optimized *S. pyogenes* Cas9 (dCas9) to quintuple tandem short peptide GCN4 in an expression vector using the EFS promoter. The 5xGCN4 fragment was synthesized by Genewiz and cloned into pEFS-dCas9-EGFP (Pregen plasmid: ZP508) with BamHI sites by Gibson Assembly to package lentiviruses (Pregen plasmid: ZP509). The aa sequence of GCN4



limma [24]. In the model, DNA methylation level at each CpG was the dependent variable and status of IS was the independent variable. The model adjusted for age, sex, BMI, smoking, alcohol consumption, hypertension, LDL-C, HDL-C, fasting plasma glucose, estimated cell counts, and surrogate variables derived from surrogate variable analysis (SVA) [25]. Multiple testing was controlled by false discovery rate (FDR), and FDR-adjusted *P*-value (i.e., *q*-value) < 0.05 was considered statistically significant.

### Region-based analysis

Differentially methylated regions (DMRs) were identified using the program DMRcate [26]. The program identifies genomic regions harboring putative disease-associated CpGs and takes into consideration the correlations between adjacent probes. Here we defined a DMR as a region containing at least 2 correlated probes (adjacent peak probes [*P* < 0.05] spaced less than 1,000 bp). A DMR with *P*-value <  $5.0 \times 10^{-7}$  was considered statistically significant.

### Enrichment and pathway analysis

To functionally annotate the identified differentially methylated genes, we conducted functional enrichment analysis using the computational program FUMA [27]. We defined differentially methylated genes as unique genes containing either DMPs or DMRs identified above. *P*-value < 0.05 was used to determine statistical significance for the annotated biological pathways.

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13148-023-01520-x>.

**Additional file 1.** The supplemental tables showing the additional results.

### Acknowledgements

We gratefully acknowledge the cooperation and participation of the members of the current study. We especially thank the clinical staff at all participating hospitals for their support and contribution to this project. Without their contribution, this research would not have been possible. Targeted bisulfite sequencing was performed by Genesky Biotechnologies.

### Author contributions

HP, YZ, and JZ conceptualized and designed the study. HP, HPG, and CST conducted the analyses. HP, MZ, CST, and JJC acquired the data. JZ, HP, and HPG drafted the manuscript. All authors critically reviewed the article and contributed to data interpretation. All authors read and approved the final manuscript.

### Funding

This study was supported by the National Natural Science Foundation of China (Nos. 82173596, 81903384, and 81872690) and a Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions. Drs. Zhao and Palma-Gudiel were supported by the National Institute of Health Grants R01DK107532, RF1AG052476, and R01AG064786.

### Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

The study protocols of CATIS were approved by the Institutional Review Boards at Soochow University in China and Tulane University in the USA. The study protocols of PMMS were approved by the Soochow University Ethics Committee. Written informed consent was obtained from all study participants. The study protocols of BasicMar and REGICOR were approved by the ethics committees of all participating hospitals, and all participants provided written informed consent to participate.

#### Competing interests

The authors declare that they have no competing interests.

Received: 24 April 2023 Accepted: 13 June 2023

Published online: 27 June 2023

### References

1. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019;18(5):439–458.
2. Li Z, Jiang Y, Li H, et al. China's response to the rising stroke burden. *BMJ.* 2019;364:l879.
3. Tsao CW, Aday AW, Almarazooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. *Circulation.* 2022;145(8):e153–639.
4. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet.* 2016;388(10046):761–75.
5. Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genome-wide associations. *Stroke.* 2012;43(12):3161–7.
6. Malik R, Chauhan G, Traylor M, et al. Multiethnic genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet.* 2018;50(4):524–37.
7. Deng G-X, Xu N, Huang Q, et al. Association between promoter DNA methylation and gene expression in the pathogenesis of ischemic stroke. *Aging (Albany, NY).* 2019;11(18):7663–77.
8. Shen Y, Peng C, Bai Q, et al. Epigenome-wide association study indicates hypomethylation of MTRNR2L8 in large-artery atherosclerosis stroke. *Stroke.* 2019;50(6):1330–8.
9. Soriano-Tárraga C, Lazcano U, Giralt-Steinhauer E, et al. Identification of 20 novel loci associated with ischaemic stroke. *Epigenetics.* 2020;15(9):988–97.
10. Davis Armstrong NM, Chen W-M, Hsu F-C, et al. DNA methylation analyses identify an intronic ZDHH6 locus associated with time to recurrent stroke in the Vitamin Intervention for Stroke Prevention (VISP) clinical trial. *PLoS ONE.* 2021;16(7): e0254562.
11. Sun H, Xu J, Hu B, et al. Association of DNA methylation patterns in 7 novel genes with ischemic stroke in the Northern Chinese Population. *Front Genet.* 2022;13.
12. Cullell N, Soriano-Tárraga C, Gallego-Fábrega C, et al. DNA methylation and ischemic stroke risk: an epigenome-wide association study. *Thromb Haemost.* 2022;(EFirst).
13. Zeng M, Zhen J, Zheng X, et al. The role of DNA methylation in ischemic stroke: a systematic review. *Front Neurol.* 2020;11: 566124.
14. He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. *JAMA.* 2014;311(5):479–89.
15. Zhang L, Guo Z, Wu M, et al. Interaction of smoking and metabolic syndrome on cardiovascular risk in a Chinese cohort. *Int J Cardiol.* 2013;167(1):250–3.



16. Roquer J, Rodríguez-Campello A, Jiménez-Conde J, et al. Sex-related differences in primary intracerebral hemorrhage. *Neurology*. 2016;87(3):257LP–262.
17. Grau M, Subirana I, Elosua R, et al. Trends in cardiovascular risk factor prevalence (1995–2000–2005) in northeastern Spain. *Eur. J. Cardiovasc. Prev. Rehabil. Off. J. Eur. Soc. Cardiol. Work. Groups Epidemiol. Prev. Card. Rehabil. Exerc. Physiol.* 2007;14(5):653–659.
18. Peng H, Fan Y, Li J, et al. DNA methylation of the natriuretic peptide system genes and ischemic stroke. *Neurol Genet*. 2022;8(3):e679.
19. Peng H, Zhang Q, Cai X, et al. Association between high serum soluble corin and hypertension: a cross-sectional study in a general population of China. *Am J Hypertens*. 2015;28(9):1141–9.
20. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics*. 2014;30(10):1363–9.
21. Houseman E, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinform*. 2012;13(1):86.
22. Pu W, Wang C, Chen S, et al. Targeted bisulfite sequencing identified a panel of DNA methylation-based biomarkers for esophageal squamous cell carcinoma (ESCC). *Clin Epigenetics*. 2017;9:129.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC<sub>T</sub></sup> method. *Methods*. 2001;25(4):402–8.
24. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015;43(7):e47.
25. Leek JT, Johnson WE, Parker HS, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics*. 2012;28(6):882–3.
26. Peters TJ, Buckley MJ, Statham AL, et al. De novo identification of differentially methylated regions in the human genome. *Epigenetics Chromatin*. 2015;8:6.
27. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun*. 2017;8(1):1826.
28. Yang L, Froio RM, Sciuto TE, et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-α-activated vascular endothelium under flow. *Blood*. 2005;106(2):584–92.
29. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2007;27(11):2292–301.
30. Gross MD, Bielinski SJ, Suarez-Lopez JR, et al. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults Study. *Clin Chem*. 2012;58(2):411–20.
31. Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. *Circ Res*. 2017;120(3):502–13.
32. Courties G, Moskowitz MA, Nahrendorf M. The innate immune system after ischemic injury: lessons to be learned from the heart and brain. *JAMA Neurol*. 2014;71(2):233–6.
33. Ozato K, Shin D-M, Chang T-H, Morse HC 3rd. TRIM family proteins and their emerging roles in innate immunity. *Nat Rev Immunol*. 2008;8(11):849–60.
34. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. *Nature*. 2004;427(6977):848–53.
35. Bahouth MN, Venkatesan A. Acute viral illnesses and ischemic stroke: pathophysiological considerations in the era of the COVID-19 pandemic. *Stroke*. 2021;52(5):1885–94.
36. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med*. 2004;351(25):2611–8.
37. van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ Res*. 2018;122(3):433–43.
38. Zeng G, Lian C, Yang P, et al. E3-ubiquitin ligase TRIM6 aggravates myocardial ischemia/reperfusion injury via promoting STAT1-dependent cardiomyocyte apoptosis. *Aging (Albany, NY)*. 2019;11(11):3536–50.
39. Mishra A, Malik R, Hachiyu T, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. *Nature*. 2022;611(7934):115–23.
40. Rangarajan ES, Primi MC, Colgan LA, et al. A distinct talin2 structure directs isoform specificity in cell adhesion. *J Biol Chem*. 2020;295(37):12885–99.
41. Castaneda AB, Petty LE, Scholz M, et al. Associations of carotid intima media thickness with gene expression in whole blood and genetically predicted gene expression across 48 tissues. *Hum Mol Genet*. 2022;31(7):1171–82.
42. von Essen M, Rahikainen R, Oksala N, et al. Talin and vinculin are down-regulated in atherosclerotic plaque; Tampere Vascular Study. *Atherosclerosis*. 2016;255:43–53.
43. Lacy SE, Bönemann CG, Buzney EA, Kunkel LM. Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins. *Genomics*. 1999;62(3):417–26.
44. Carty CL, Keene KL, Cheng Y-C, et al. Meta-analysis of genome-wide association studies identifies genetic risk factors for stroke in African Americans. *Stroke*. 2015;46(8):2063–8.
45. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. *Nat Rev Dis Prim*. 2019;5(1):56.
46. Adan A, Archer SN, Hidalgo MP, et al. Circadian typology: a comprehensive review. *Chronobiol Int*. 2012;29(9):1153–75.
47. Fan M, Sun D, Zhou T, et al. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. *Eur Heart J*. 2020;41(11):1182–9.
48. Domínguez F, Fuster V, Fernández-Alvira JM, et al. Association of sleep duration and quality with subclinical atherosclerosis. *J Am Coll Cardiol*. 2019;73(2):134–44.
49. Zhao Y, Lu X, Wan F, et al. Disruption of circadian rhythms by shift work exacerbates reperfusion injury in myocardial infarction. *J Am Coll Cardiol*. 2022;79(21):2097–115.
50. Braun PR, Han S, Hing B, et al. Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals. *Transl Psychiatry*. 2019;9(1):47.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

